1. Home
  2. CLB vs ESPR Comparison

CLB vs ESPR Comparison

Compare CLB & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Core Laboratories Inc.

CLB

Core Laboratories Inc.

HOLD

Current Price

$14.01

Market Cap

864.2M

Sector

N/A

ML Signal

HOLD

Logo Esperion Therapeutics Inc.

ESPR

Esperion Therapeutics Inc.

HOLD

Current Price

$3.13

Market Cap

731.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLB
ESPR
Founded
1936
2008
Country
United States
United States
Employees
3300
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
864.2M
731.9M
IPO Year
2023
2013

Fundamental Metrics

Financial Performance
Metric
CLB
ESPR
Price
$14.01
$3.13
Analyst Decision
Hold
Strong Buy
Analyst Count
2
4
Target Price
$12.50
$8.75
AVG Volume (30 Days)
521.7K
17.5M
Earning Date
04-29-2026
05-07-2026
Dividend Yield
0.23%
N/A
EPS Growth
N/A
60.71
EPS
N/A
N/A
Revenue
$526,520,000.00
$403,135,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.75
$12.81
P/E Ratio
N/A
N/A
Revenue Growth
0.51
21.31
52 Week Low
$9.72
$0.81
52 Week High
$20.36
$4.18

Technical Indicators

Market Signals
Indicator
CLB
ESPR
Relative Strength Index (RSI) 44.57 70.17
Support Level $13.72 $3.11
Resistance Level $17.05 $3.18
Average True Range (ATR) 0.60 0.02
MACD 0.18 -0.01
Stochastic Oscillator 62.78 50.00

Price Performance

Historical Comparison
CLB
ESPR

About CLB Core Laboratories Inc.

Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.

About ESPR Esperion Therapeutics Inc.

Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.

Share on Social Networks: